Clinical trial
A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
NCT00994123 is registered in ClinicalTrials.gov with Merrimack Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1-2 Trial of MM-121 in Combination With Erlotinib in Three Groups of Patients With Non-Small Cell Lung Cancer
- Lead sponsor
- Merrimack Pharmaceuticals
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- February 28, 2010
- Completion date
- June 30, 2015
- Enrollment
- 162 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.